chrisvoncsefalvay/vaers-outcomes huggingface dataset:
About 3 to 4 days later, he started developing tingling of his face, precisely on his left side of the face; This is a spontaneous report from a contactable consumer (patient himself). A 65-year-old male patient received bnt162b2 (BioNTech COVID-19 vaccine; formulation: solution for injection; COVID Vaccine manufacturer: Unspecified; NDC number, UPC number, and Expiry Date: Unknown), dose 2 via an unspecified route of administration on 19Feb2021 (lot number: EL9269) as dose 2, single for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient historical vaccine includes bnt162b2 (BioNTech COVID-19 vaccine; lot number: not reported), dose 1 on 24Jan2021 as dose 1, single for Covid-19 immunisation. Consumer stated that the reason he called was because he just heard on the news with the Johnson and Johnson Covid vaccine that people were getting some tingling in their legs and he don't know if this was something that Pfizer knows about but four days of getting the second Covid vaccine from Pfizer, he had tingling in his face every day now and he reported that he received his second dose of the Pfizer BioNTech COVID-19 vaccine on 19Feb2021 and about 3 to 4 days later, he started developing tingling of his face, precisely on his left side of the face began sometime in Feb2021. He would like to know if this side effect has been reported with the Pfizer BioNTech COVID-19 vaccine. No PQC was reported. There is a medical information request. The outcome of the event was not recovered.
almost immediately started feeling warm and dizzy, stated I don't feel right. Had him lie down, administered O2 at 2l/m for feeling of SOB. B/P was elevated at 197/97, O2 sat 98%, heart rate was tachycardia at 140's. Had patient lie down while being monitored. HR slowly came down, B/P systolic dropped 30 points to 160's
Approximately 24-36 hours after injection, experienced aches, chills, shooting pain in hands, fever, sweating.
Moderna-covid 19 vaccine EUA- 9 days after 2nd dose shot started with hive rash to B/L arms, back and legs; rash noted on arms and legs near joints and only occurring at night, resolved in am and reoccured on day 10 post vaccine
Adverse drug reactions (including pain) after human papillomavirus (HPV) vaccine; Adverse drug reactions (including pain) after human papillomavirus (HPV) vaccine; product origin unk; This spontaneous social media report was received from an other health professional and refers to a female patients in age between 12 to 24 years old. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On an unknown date, the patient was vaccinated with human papillomavirus (HPV) vaccine (manufacturer unknown) (dose, route of administration, lot #, expiration date were not reported) for prophylaxis. On unknown day, the patient experienced undesirable drug effects (including pain). The outcomes of the events were not reported.  The events were considered as related to human papillomavirus (HPV) vaccine (manufacturer unknown).  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2107USA001853: US-009507513-2107USA008730: US-009507513-2107USA008731: US-009507513-2107USA008729: US-009507513-2107USA008733: US-009507513-2107USA008728: US-009507513-2107USA008727:
vaccine placed on 11/27, on 12/8 pt states she noted redness, swelling and soreness to right posterior arm where varivax vaccine administered. Took tylenol to relieve the pain which helped. Also notes 2 days later felt pain radiating to left shoulder as well. This resolved the next day. Seen on 12/11 at clinic and redness, soreness, and swelling to posterior arm continues but is improved.
Healthcare worker reported that a patient developed injection site reaction after receiving PNEUMOVAX 23.  The patient's arm was swollen and warm to the touch.   No additional AEs were reported. No further information provided.  No PQC.; Healthcare worker reported that a patient developed injection site reaction after receiving PNEUMOVAX 23.  The patient's arm was swollen and warm to the touch.   No additional AEs were reported. No further information provided.  No PQC.; Healthcare worker reported that a patient developed injection site reaction after receiving PNEUMOVAX 23.  The patient's arm was swollen and warm to the touch.   No additional AEs were reported. No further information provided.  No PQC.; This spontaneous report was received from Other Health Professional and refers to a 34-year-old male.  The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant medications included salbutamol (ALBUTEROL HFA), bictegravir sodium (+) emtricitabine (+) tenofovir alafenamide fumarate (BIKTARVY), clindamycin (CLINDAMYCIN), cyclobenzaprine (CYCLOBENZAPRINE), nicotine (NICOTINE), curcuma longa rhizome (+) piper nigrum fruit (TURMERIC +) and varenicline (VARENICLINE).   On 30-JUN-2023, the patient started therapy with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) injection, lot #W007035, expiration date: 20-OCT-2023 (strength, route of administration, and indication were not provided).  On 01-JUL-2023, healthcare worker reported that a patient developed injection site reaction after receiving PNEUMOVAX 23. The patient's arm was swollen and warm to the touch. No additional AEs were reported. No further information provided. No PQC. At the time of reporting, the patient was recovering from the event of Vaccination site warmth, Vaccination site swelling and Vaccination site reaction.  The action taken with PNEUMOVAX23 regarding events was reported as Not Applicable.  The causal relationship between events and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was unknown.
complaining of pain in her arm area/upper arm area/lingering sore arm; pain in her shoulder area; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE PAIN (complaining of pain in her arm area/upper arm area/lingering sore arm) and ARTHRALGIA (pain in her shoulder area) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041J21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. In December 2021, the patient experienced VACCINATION SITE PAIN (complaining of pain in her arm area/upper arm area/lingering sore arm) and ARTHRALGIA (pain in her shoulder area). The patient was treated with IBUPROFEN for Adverse event, at an unspecified dose and frequency and PARACETAMOL (TYLENOL [PARACETAMOL]) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (complaining of pain in her arm area/upper arm area/lingering sore arm) and ARTHRALGIA (pain in her shoulder area) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.
administration of two 0.5 ml doses of PEDVAXHIB to a 12 month old; administration of two 0.5 ml doses of PEDVAXHIB to a 12 month old; No additional adverse events reported; This spontaneous report was received from a licensed practical nurse and refers to a 12-month-old patient. No information regarding the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant medications was provided.  On an unknown date, the patient was vaccinated with a dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) 0.5 ml (formulation, route of administration, anatomical location, lot # and expiration date were not reported) for prophylaxis. On an unknown date, the patient was vaccinated with an additional dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) 0.5 ml (formulation, route of administration, anatomical location, lot # and expiration date were not reported) for prophylaxis (inappropriate schedule of product administration and incorrect dose administered). No additional adverse events reported.
Some doses that may have been administered past 30 days from being thawed/The vaccines were applied to patients after being refrozen; Some doses that may have been administered past 30 days from being thawed/The vaccines were applied to patients after being refrozen; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Some doses that may have been administered past 30 days from being thawed/The vaccines were applied to patients after being refrozen) and PRODUCT STORAGE ERROR (Some doses that may have been administered past 30 days from being thawed/The vaccines were applied to patients after being refrozen) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Some doses that may have been administered past 30 days from being thawed/The vaccines were applied to patients after being refrozen) and PRODUCT STORAGE ERROR (Some doses that may have been administered past 30 days from being thawed/The vaccines were applied to patients after being refrozen). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Some doses that may have been administered past 30 days from being thawed/The vaccines were applied to patients after being refrozen) and PRODUCT STORAGE ERROR (Some doses that may have been administered past 30 days from being thawed/The vaccines were applied to patients after being refrozen) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications are provided.  No treatment medications are provided.
All joints painful from hands to knees/ fatigue / underarm lymph nodes hurt. Not reported to physician yet. Taking Motrin 400 mg for pain.
Pt developed fatigue, pain in back and limbs (severe), sore muscles, excessive hair loss, loss of appetite, alternating constipation and diarrhea, numbness in her left arm (site of injection) and nausea. Diagnosed with perfuse myalgia. Per 1 year followup: Pt has not recovered. Muscle and joint pain. Fatigue. Diminished motor skills, loss of critical thinking skills. Depression. Intermittent blurred vision. Loss of ability to work. Insomnia. Comments: I wish I never agreed to be vaccinated with the Hep B recombinant vaccine. It has uined my quality of life! Thank you for caring. 01/08/2003 Pt
Information has been received from a pharmacy technician concerning a female patient who on 20-MAR-2009 was vaccinated with ZOSTAVAX (Merck). Subsequently the patient developed redness at the injection site. Additional information has been requested.
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies were not reported. On an unknown date, the patient was vaccinated with improperly stored ZOSTAVAX, lot # N019921, expiration date 05-JUL-2018, for prophylaxis (dose and route of administration were not reported). The vaccine was reconstituted with properly stored sterile diluent (STERILE DILUENT). The vaccine underwent a temperature excursion between 6 to 14 degrees Fahrenheit degrees for 12 hours. No previous temperature excursions were reported. Digital data logger was involved in recording the excursion details. No adverse effects were reported.
Heart pounding really bad; Vertigo feeling; Legs feel jello like; Jittery feeling; Sore arm; Tired; Feeling queasy; This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (Heart pounding really bad), VERTIGO (Vertigo feeling), MUSCULAR WEAKNESS (Legs feel jello like), FEELING JITTERY (Jittery feeling) and PAIN IN EXTREMITY (Sore arm) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PALPITATIONS (Heart pounding really bad), VERTIGO (Vertigo feeling), MUSCULAR WEAKNESS (Legs feel jello like), FEELING JITTERY (Jittery feeling), PAIN IN EXTREMITY (Sore arm), FATIGUE (Tired) and NAUSEA (Feeling queasy). At the time of the report, PALPITATIONS (Heart pounding really bad), VERTIGO (Vertigo feeling), MUSCULAR WEAKNESS (Legs feel jello like), FEELING JITTERY (Jittery feeling), PAIN IN EXTREMITY (Sore arm), FATIGUE (Tired) and NAUSEA (Feeling queasy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product used was not provided by the reporter.  Treatment information was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 04-May-2021: Follow-up information will be processed at the same time as the initial report. Follow-up updated outcome for events.
Rt arm hot red swollen area on 8-4-12. Became increasingly red & warm measure 12 x 5 inches, low grade fever x 2 days. Area swollen with fluid over elbow.
Woke late evening with stabbing sensation at side of rt breast. Turned on light notice red band from injection ares to under right armpit as well as swollen nodes. In Am of the 4th armpit had extremely large mass size of a small lemon. The red banded area was now swollen and hard along length.
Woke up today and reported to his mother that his left foot and ankle were hurting and itching.  When mom looked at the left leg, she said that it  had a rash  with a few small blisters on it.  She put anti-itch cream on it and sent him to school.
Pt reported that she feel dizzy and feel  like lymph swell. After 20 min, we offered her Benadryl  25mg  x 1 and monitor after another 20 min she called  her dad to pick her up. She  was well alert and walked normally and her dad  escorted  home .  She did not want stay.  We offered to call 911 or let  her  know she has any sign  of trouble breathing call 911.
fever after the 2nd dose; chills after the 2nd dose; This spontaneous case was reported by a patient and describes the occurrence of PYREXIA (fever after the 2nd dose) and CHILLS (chills after the 2nd dose) in a female patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever after the 2nd dose) and CHILLS (chills after the 2nd dose). At the time of the report, PYREXIA (fever after the 2nd dose) and CHILLS (chills after the 2nd dose) outcome was unknown.            Concomitant medication details were not reported by the reporter. Treatment details was not reported by the reporter.   This case was linked to MOD-2022-645572, MOD-2022-645567 (Patient Link).   Reporter did not allow further contact
Headache; Local and systemic pain at injection site; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) and VACCINATION SITE PAIN (Local and systemic pain at injection site) in a 37-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced HEADACHE (Headache) and VACCINATION SITE PAIN (Local and systemic pain at injection site). At the time of the report, HEADACHE (Headache) and VACCINATION SITE PAIN (Local and systemic pain at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. The reporter asked if the patient could self administer Tylenol (paracetamol) to treat symptoms.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
Woke up the 20th with a headache, took aspirin. Aspirin didn't help, waited 4 hrs then took generic otc sinus & allergy. Took edge off but then started head congestion, scratchy throat, feverish & tired. Got up on the 21st feeling quite sick; head congested, throat sore, aching all over and weak. Spoke to personal physicians office & explained to them that I received the H1N1 vaccine the 18th. They said I was having a reaction to the shot & that the symptoms should go away in a couple days. Started taking Thera-flu that evening to help alleviate the symptoms and sleep. Today the 22nd, still feeling the same as day before & taking Thera-flu. If symptoms don't improve in a couple days, will seek medical attention.
Arthritis flare after 2nd dose of Pfizer Covid vaccine. Worse ever unable to close right hand for 3-4 days. Pain is persist with little relief from anti inflammatory medication.
Uncontrollable crying in both (twins), redness and swelling at injection site and leg, sleepiness, loss of appetite, loss of recognition, muscle control, spasms, lethargy.
Watery stools x 4 on 10/1, no fever. Blood noted in stool 10/2, diarrhea resolved and stools mushy by afternoon 10/2 but still + blood, though not visible.
Bilateral enlarged axillary lymph nodes; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 45 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left (Lot number: EL9262) as dose 1, single and administered in arm right (Lot number: EN6200) as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: SYNTHROID. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 18Feb2021, outcome "not recovered", described as "Bilateral enlarged axillary lymph nodes". The event "bilateral enlarged axillary lymph nodes" was evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of lymphadenopathy.  Additional information: The patient did not receive any vaccination prior to covid and did not tested for covid post vaccination. No allergies. The patient did not  receive any other vaccines within 4 weeks prior to the COVID vaccine.  Follow-up attempts completed. No further information expected.
Red, tender area below injection site 4" oval, extending to injection site. Still red on 3/12/01. Treated with Benadryl, Tylenol and ice.
Received vaccine 11.5.12. Noticed itching of upper chest 11.6.12. Noticed red rash that evening. No progression of rash since then redness/swelling/tenderness at injection site.
Expired dose administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of expired vaccine used in a 55-year-old male patient who received Herpes zoster (Shingrix) (batch number 9ey93, expiry date 15-APR-2023) for prophylaxis.   On 17-APR-2023, the patient received Shingrix. On 17-APR-2023, an unknown time after receiving Shingrix, the patient experienced expired vaccine used (Verbatim: Expired dose administered). The outcome of the expired vaccine used was unknown.   Additional Information: GSK Receipt Date: 21-APR-2023 The vaccine administration facility was the same as primary reporter. The reporter did consent to follow up via email. The patient received a Shingrix which was already expired, which led to expired vaccine used. This case had been linked with US2023059006 by same reporter for different patient.; Sender's Comments:  US-GSK-US2023059006:Same report/Other patient
Long lasting, hives on both arms, both hands, both legs, and groin. At this point, I am 2 weeks and 3 days after my second shot and I have had the hives since 5 days after my first shot.
No adverse event; Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated; This spontaneous case was reported by a nurse and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated) and NO ADVERSE EVENT (No adverse event) in a 2-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 214K22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 29-Apr-2023, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 10 microgram. On 29-Apr-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated) and NO ADVERSE EVENT (No adverse event) outcome was unknown. Not Provided      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient of 6 months-5 years of age received a Moderna COVID-19, bivalent vaccine from the Pink cap vial(10 mcg) instead of blue cap vial(25 mcg), when blue cap was indicated).    On 27-Mar-2023, the patient received first dose of monovalent vaccine (Batch/Lot number: AS1903B and Dose/volume: 25 micrograms).  Concomitant product use was not provided by the reporter.  The route of administration of suspect Moderna monovalent was reported as Mono and bivalent was reported as BI.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-730780 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-730780:Master case
Systemic Reactions: Grade 3: fatigue, myalgia, muscle weakness beginning <8hrs of vaccination and continuing for 2 days; Grade 2: fever and chills beginning <8hrs of vaccination and continuing for 24h Local Reactions: Grade 2-3: Injection site pain beginning <8h of vaccination and resolving over 5 days.
Pt recv vax on 4/14/99; on 4/15/99 pt exp fever (102), vomiting, local redness; tx=Tylenol